CellTech Pharmed

What CellTech Pharmed does

CellTech Pharmed (سل تک فارمد) is a privately held, knowledge-based cell therapy and regenerative medicine company founded in February 2014 through collaboration between Barakat Pharmaceutical Group and Royan Institute, headquartered in Tehran, Iran. The company operates a GMP-certified manufacturing facility launched in 2017 and self-describes as the largest cell therapy factory in the Middle East, holding ISO 13485:2016, ISO 9001:2015, and GMP certifications alongside an accredited quality control laboratory. Its core competency is isolating and expanding mesenchymal stem cells (MSCs) from human umbilical cord Wharton's Jelly under GMP conditions, supplemented by autologous fibroblast and melanocyte processing and exosome isolation via multi-step differential ultracentrifugation.

The commercial portfolio comprises four trademarked, IFDA-approved or registered products: WhartoCell (allogeneic UC-MSC therapy for osteoarthritis and neurological indications including MS, cerebral palsy, and autism), ReColorCell (autologous melanocyte/keratinocyte transplantation for vitiligo, reported 65% improvement rate, covering approximately 200 cm² with a lifelong effect), RenuDermCell/Lavicell (autologous fibroblast therapy for skin rejuvenation), and ExoZist (exosome therapy available in 3mL vials at 1×10⁹ or 1×10¹⁰ particle concentrations). ReColorCell became the first cell therapy product registered in Iran's official drug list in 2018, and WhartoCell received IFDA approval for osteoarthritis treatment in 2024-2025.

CellTech generates revenue through a hybrid B2B/B2C model: direct-to-physician prescription via a registered doctor portal, patient self-enrollment through a dedicated portal, health tourism for international patients (notably from the UAE), technology transfer and licensing programs for partner-manufactured or partner-administered therapies, premium stem cell line sales and consulting for research institutions, and accredited laboratory testing services. Pricing is not publicly disclosed and is set via direct consultation, with the company publicly committed to making cell therapy more affordable. End customers are individual patients in neurology, orthopedics, dermatology, and aesthetic indications, with secondary B2B customers including hospitals, universities, and biotech firms seeking manufacturing partnerships or lab services.

Name

CellTech Pharmed

Legal name

سل‌تک فارمد (CellTech Pharmed Co.)

Website

https://celltech.ir

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

CellTech Pharmed is an Iranian GMP-certified cell therapy company developing allogeneic umbilical cord MSC, autologous fibroblast, melanocyte, and exosome products for osteoarthritis, neurological disorders, vitiligo, and skin rejuvenation, serving patients via physician-prescribed treatment and international health tourism.

Ownership category

akta.pro rank

Product category

Cell Therapy Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Autologous) (HLAAABAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Cell therapy products
• Regenerative medicine
• Stem cell manufacturing
• Exosome therapeutics
• Biologics GMP manufacturing

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cell Therapy Products: Sale of approved cell therapy products including WhartoCell, ReColorCell, RenuDermCell, and ExoZist to patients and healthcare providers. Products are prescribed by physicians and administered in clinical settings.
2. Health Tourism Services: International patients receive cutting-edge cell therapy treatments in Iran. The company offers health tourism services to make treatments accessible to patients from other countries.
3. Technology Transfer Programs: Celltech offers technology transfer programs: 'Production at CellTech, treatment by partner' where they handle manufacturing while partners deliver patient care, and full production technology transfer to help partners establish local production infrastructure.
4. Premium Stem Cell Lines and Consulting: Sale of premium-quality stem cell lines for research and therapeutic pipelines. Specialized consultation services in stem cell research, product development, and clinical translation.
5. Laboratory Testing Services: Accredited laboratory services including sterility testing, bacterial endotoxin detection, mycoplasma PCR testing, flow cytometry surface markers, cell count and viability assays, pH determination, conductivity, microbial limit tests, environmental monitoring of cleanrooms, cell culture efficacy tests, growth promotion tests, antiseptic efficacy testing, and microbiological media preparation.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

CellTech Pharmed develops, manufactures, and commercializes GMP-certified cell-based and cell-free regenerative medicine products. Its portfolio includes allogeneic umbilical cord mesenchymal stem cell therapy (WhartoCell), autologous melanocyte transplantation for vitiligo (ReColorCell), autologous fibroblast therapy for skin rejuvenation (RenuDermCell), and MSC-derived exosome therapy (ExoZist). The company also operates accredited laboratory testing services and technology transfer programs for partners.

Product overview

CellTech Pharmed offers a portfolio of four regenerative medicine products: WhartoCell® (allogeneic umbilical cord MSC therapy for neurological and orthopedic conditions), ReColorCell® (autologous melanocyte transplantation for vitiligo), RenuDermCell® (autologous fibroblast therapy for skin aging), and ExoZist® (purified MSC-derived exosome therapy for tissue repair). The company operates GMP-certified facilities and focuses on cell-based and cell-free therapeutic approaches for unmet medical needs in neurology, orthopedics, and dermatology.

Differentiator

Problem solved

Functional benefit

Brands

• WhartoCell®: Allogeneic human umbilical cord mesenchymal stem cell (MSC) therapy product derived from Wharton's Jelly. Used for neurological disorders (cerebral palsy, multiple sclerosis, autism) and orthopedic conditions (osteoarthritis).
• ReColorCell®
• RenuDermCell®
• ExoZist®

Products and services

• WhartoCell® (Allogeneic MSC Therapy) Allogeneic human umbilical cord mesenchymal stem cell (MSC) therapy derived from Wharton's Jelly, suspended in sterile normal saline. Indicated for neurological disorders (autism, cerebral palsy, multiple sclerosis) and orthopedic conditions (osteoarthritis, sports injuries). IFDA-approved.
• ReColorCell® (Autologous Melanocyte Transplantation) Autologous cell therapy product for vitiligo treatment. Keratinocytes and melanocytes are isolated from the patient's own skin under sterile conditions and transplanted into depigmented areas. Clinical studies showed a 65% improvement rate with approximately 200 cm² skin coverage and lifelong effect.
• RenuDermCell® (Autologous Fibroblast Therapy) Autologous cultured human dermal fibroblast therapy for skin rejuvenation. A skin biopsy is taken, fibroblasts are cultured and expanded in vitro, then reinjected to stimulate natural collagen and elastin production, addressing chronological aging, photoaging, wrinkles, and acne scars.
• ExoZist® (Exosome Therapy) Next-generation exosome-based product derived from human umbilical cord MSCs, isolated using multi-step differential ultracentrifugation. Available in 3mL sterile vials with 1x10^9 or 1x10^10 particle content. Indicated for tissue repair, rejuvenation, dermatological applications, sports medicine, and orthopedic applications.
• Accredited Laboratory Testing Services Laboratory services including sterility testing, bacterial endotoxin detection, mycoplasma PCR testing, flow cytometry surface markers, cell count and viability assays, pH determination, conductivity, microbial limit tests, environmental monitoring of cleanrooms, cell culture efficacy tests, growth promotion tests, antiseptic efficacy testing, and microbiological media preparation. Offered to pharmaceutical researchers, universities, and biotech companies.
• Technology Transfer Program Two-track technology transfer offering: (1) 'Production at CellTech, treatment by partner' where CellTech handles manufacturing and partners deliver patient care, and (2) full production technology transfer to help partners establish local cell therapy production infrastructure.
• Health Tourism Services Medical tourism services that enable international patients (including from the UAE and other regional markets) to access CellTech's cell therapy treatments in Iran, with treatment coordination and consultation services facilitated by the company.
• Premium Stem Cell Lines and Consulting Sale of premium-quality stem cell lines for research and therapeutic pipelines, paired with specialized consultation services in stem cell research, product development, and clinical translation.

Quantifiable outcome

• 65% improvement rate in vitiligo patients treated with ReColorCell
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, major and minor.

• Barekat Pharmaceutical Group (گروه دارویی برکت)coreStrategic or Co-development PartnerBarekat Pharmaceutical Group was a co-founding partner in establishing Celltech Pharmed in 2014. The group provides pharmaceutical industry expertise, manufacturing infrastructure, and distribution network support. Celltech participated in exhibitions under the Barekat booth.
• Royan Institute (پژوهشگاه رویان)coreStrategic or Co-development PartnerRoyan Institute was a co-founding partner in establishing Celltech Pharmed. The institute provides stem cell research expertise and clinical trial support. Joint clinical studies have been conducted for WhartoCell product.
• Royan Stem Cell Technology Company - Isfahan (شرکت فناوری بن یاخته های رویان اصفهان)majorStrategic or Co-development PartnerDr. Zarrebi, CEO of Royan Stem Cell Technology Company, collaborated with Celltech Pharmed at the VANA International Congress. The companies have conducted joint clinical studies including first injection of WhartoCell in knee osteoarthritis patients.
• Islamic Azad University Medical Science Unit Tehran (دانشگاه آزاد واحد علوم پزشکی تهران)minorStrategic or Co-development PartnerDr. Maryam Eslami, representative of the university presidency, visited Celltech Pharmed facilities on February 1, 2022. Potential research collaboration was discussed.
• Iran Food and Drug Administration (IFDA/IR-FDA)coreOthersIFDA provides regulatory approval and oversight for cell therapy products. They granted market authorization for ReColorCell as the first cell therapy product in Iran's drug list, and approved WhartoCell for osteoarthritis treatment.
• Union Hospital / Huazhong University (China)minorStrategic or Co-development PartnerResearch collaboration on umbilical cord stem cell therapy for knee osteoarthritis. Union Hospital researchers published positive clinical results on MSC therapy for osteoarthritis.
• Samsung Medical Center and Sungkyunkwan University (South Korea)minorStrategic or Co-development PartnerResearch collaboration on cartilage repair using umbilical cord blood-derived MSCs combined with hyaluronic acid hydrogel. Published clinical results showing cartilage regeneration maintained for 7 years.
• University of Milan (Italy)minorStrategic or Co-development PartnerResearch collaboration on hip osteoarthritis treatment with mesenchymal stem cells. Studies showed potential to delay or avoid hip replacement surgery.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/celltech-pharmed
• Instagraminstagram.com/celltechpharmed

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellTech Pharmed